SCHEMBL30234817

SCHEMBL30234817

Cc1cc(Nc2ccc(NC(=O)OC(C)(C)C)cc2)nc(N2CCCC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HPGD P15428 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ GALR2 O43603 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ MAPK1 P28482 1/20 0.50
▸ TAAR1 Q96RJ0 1/20 0.50
▸ CCNE1 P24864 5/20 0.48
▸ CDK2 P24941 5/20 0.48
▸ GALR1 P47211 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ ROCK2 O75116 2/20 0.44
▸ ROCK1 Q13464 1/20 0.44
▸ APOBEC3A P31941 1/20 0.44
▸ APOBEC3G Q9HC16 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30234299 0.91 LMNA (0.65) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL23867651 0.80 LMNA (0.53) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL18063521 0.80 MAPT (0.58) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL30234230 0.79 APOBEC3A (0.49) POLBAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL20042175 0.79 CCNE1 (0.55) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL30165660 0.79 CCNE1 (0.43) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL23867649 0.78 ALDH1A1 (0.52) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL18153288 0.78 CCNE1 (0.58) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL23859940 0.76 MAPT (0.62) LMNAHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL11506640 0.76 GALR2 (0.66) LMNAKDM4EGALR2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338898-A Small molecule inhibitors of oncogenic CHD1L with preclinical anti-colorectal cancer activity 科罗拉多州立大学董事会(法人团体) 2024-07-12 — — CN disclosed
US-20230103444-A1 SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER UNITED STATES GOVERNMENT 2023-04-06 — — US disclosed
WO-2023055763-A2 SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2023-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103444-A1 SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER CHD1L, CHD1, CHD9 LMNA 3833/4885HSD17B10 1551/4885ALDH1A1 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback